INmune Bio's Stock Surges Amid Phase II Trial Progress

Introduction

INmune Bio, Inc. (NASDAQ: INMB; Korean: 인뮨 바이오) is a clinical-stage biotechnology company based in Boca Raton, Florida. Founded in September 2015, the company develops therapies that utilize the patient’s innate immune system to address diseases associated with inflammation and residual cancer cells. Its principal programs include XPro™ (soluble TNF inhibitor) for neuroinflammatory conditions, INKmune™ for natural killer (NK) cell activation in oncology, and CORDStrom™ for rare dermatological disorders.

Corporate Structure and Leadership

INmune Bio has between 11 and 50 employees, and its management team comprises individuals with diverse expertise in scientific, clinical, and financial domains:

• Raymond J. Tesi, MD (CEO) has led the company since its inception, with prior experience as CEO of FPRT Bio and Coronado Biosciences and training as a transplant surgeon.
• David J. Moss (CFO) has co-founded several ventures since 1995 and holds an MBA from Rice University.
• Professor Mark Lowdell, PhD (CSO/CMO) oversees translational immunotherapy initiatives and has been affiliated with University College London since 1994.
• Christopher J. Barnum, PhD (VP, Neuroscience) specializes in neuroimmunology and biomarker-driven therapies for central nervous system conditions.
• Joshua S. Schoonover, Esq. (General Counsel) manages intellectual property strategy and licensing matters.
• Tara Lehner (VP, Clinical Operations) is responsible for trial design and execution.

Biotechnology by National Cancer Institute

Recent Developments and News

• January 28, 2025: The first patient was treated with the medium dose of INKmune™ in the Phase II portion of a Phase I/II clinical trial for metastatic castration-resistant prostate cancer at the West Los Angeles VA Medical Center, overseen by principal investigator Matthew Rettig, MD.
• March 27, 2025: INmune Bio reported its financial results for the year ending December 31, 2024. Key highlights included:
  • Completion of enrollment for the AD02 global, blinded, randomized Phase II trial in Alzheimer's disease with 208 patients.
  • Interim analyses of the EMACC cognitive endpoint indicating significant correlation (p<0.001) with Clinical Dementia Rating-Sum of Boxes.
  • Publication in Cell Reports indicating soluble TNF's role in microglial remyelination.
  • Reported improvements in electroencephalography (EEG) biomarkers and changes in synaptic proteins following XPro™ treatment.
• June 16, 2025: Two Form S-8 filings registered 3,324,550 shares under the 2017 and 2019 Stock Incentive Plans and an additional 2,500,000 shares under the 2021 Plan, reinforcing equity-based compensation for employees.
• June 26, 2025: A Form 8-K filing (items 8.01 and 9.01) was submitted to the SEC, reporting material corporate events.
• December 4, 2024: INmune Bio announced a partnership with OmniScience to implement Vivo, a generative AI-powered control tower for data integration and analysis in the AD02 trial.

Financial and Strategic Analysis

As of June 27, 2025, INMB's stock closed at $10.02, reflecting an increase of 59.55% on a trading volume of 3,214,462 shares. The 52-week price range is $4.32 to $10.50, with an approximate market capitalization of $152.6 million. Reported revenue for the trailing twelve months was $50,000, with a net loss of $40.8 million and a diluted EPS of –$1.93. The company reported $19.3 million in cash and a debt-to-equity ratio of 1.17%. Valuation multiples include a price/sales ratio of 2,690 and a price/book ratio of 5.03, reflecting its early-stage pipeline position.

INmune Bio's approach aligns clinical trial designs with patient biology, focusing on measurable clinical benefits. Its DN-TNF platform addresses neuroinflammation in Alzheimer’s disease, while INKmune aims to enhance NK cell activity against residual cancer cells. CORDStrom™, currently in development for epidermolysis bullosa, has achieved FDA designations as a Rare Pediatric Disease and Orphan Drug.

Market Position and Industry Context

INmune Bio operates within the immunology/immuno-oncology sector, facing competition from established pharmaceutical companies and emerging biotechs focused on cell therapy and neuroinflammation. The company's beta of 1.57 indicates greater volatility compared to the S&P 500. The Alzheimer's treatment market increasingly emphasizes neuroinflammatory targets, with XPro™ positioned as a unique solution. NK cell therapies continue to gain interest within oncology, and INKmune™ is part of this expanding field. Collaborations with VA medical centers and partnerships with AI technology firms suggest a strategy to leverage real-world data and advanced analytics in clinical development.

TL;DR

On June 27, 2025, INmune Bio’s stock increased 59.55% to $10.02 following a Form 8-K filing submitted on June 26. The company is progressing its Phase II AD02 Alzheimer’s trial utilizing AI-driven data analysis via OmniScience’s Vivo platform and has commenced Phase II treatment in its prostate cancer trial at the West LA VA Medical Center. Two S-8 registrations on June 16 added 5.8 million shares intended for employee incentive plans. Top-line cognitive results from the AD02 trial are anticipated in Q2 2025, supported by $19.3 million in cash to fund ongoing clinical operations.